Posts by: Margarida Azevedo

Margarida Azevedo

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

June 7, 2016

In Study of Benign Prostatic Obstruction Treatment, Researchers Review Efficacy, Safety of Thulium Laser

News

Researchers at the Columbia University Medical Center examined the existing literature on high power thulium laser, a technique introduced in 2005 for the surgical treatment of benign prostatic obstruction. The ... Read more

May 31, 2016May 31, 2016

BPH Therapy That Stabilizes Estrogen Receptor β May Work Best, Study Suggests

News

Researchers recently studied the biochemical pathways involved in the mechanism of action of BOH combination therapy with 5α- reductase (5AR) inhibitors, such as dutasteride, and nonsteroidal anti-inflammatory drugs (NSAIDs). Their ... Read more

May 26, 2016May 26, 2016

Phytotherapy Mostly Ineffective for BPH Management, According to Data Review

News

Albert Einstein College of Medicine researchers have reviewed clinical data concerning the use of phytotherapy for the management of benign prostatic hyperplasia (BPH) and found that early clinical trials that seemed efficacious had significant ... Read more

May 16, 2016May 16, 2016

BPH Patients Treated with Rezūm System Have Improved LUTS, According to Data

News

NxThera, a therapeutic device company responsible for the development of the Convective Water Vapor Energy (WAVE) technology platform, presented the sexual function preservation data from a trial evaluating the Rezūm system for ... Read more

May 12, 2016May 12, 2016

Potential LUTS Treatment, Onabotulinum Toxin A, May Work by Blocking an Inflammatory Neuropeptide

News

A potent neurotoxin known as Onabotulinum toxin A appears to treat lower urinary tract symptoms (LUTS) by inhibiting a neuropeptide involved in inflammation and pain, researchers investigating the toxin’s mechanism of ... Read more

May 10, 2016May 10, 2016

BPH Associated with Higher Risk of Prostate and Bladder Cancer in Study

News

Researchers investigating a possible correlation between benign prostate hyperplasia (BPH) and certain urologic male cancers found that BPH can be a risk factor for prostate and bladder cancer, especially in Asian patients. The ... Read more

April 20, 2016April 20, 2016

Researchers Review BPH Risk Factors with View to New Therapeutic Approaches

News

A recent literature review concluded there are different hormonal pathways leading to the pathogenesis of benign prostatic hyperplasia (BPH), primarily androgens and their receptors, growth factors, and estrogen. Researchers believe such knowledge ... Read more

April 13, 2016April 13, 2016

Prostate Embolization Is Effective Therapy Alternative in Men with Enlarged Prostate and LUTS, Study Finds

News

Researchers from the Universidade Nova de Lisboa in Portugal have investigated the efficacy of prostate artery embolization (PAE) as a therapy for patients with benign prostatic hyperplasia (BPH), finding it can ... Read more

April 7, 2016April 7, 2016

In Study of Men with LUTS and Enlarged Prostate, Dutasteride Improved Bone Mineral Density

News

Researchers at the Department of Renal and Urologic Surgery at Japan’s Asahikawa Medical University examined the effect of dutasteride, a 5α-reductase inhibitor, on the bone mineral density (BMD) of aging male ... Read more

March 22, 2016March 23, 2016

BPH Disease Progression Linked to Pro-inflammatory Factors, Immune Cell Chronic Activation

News

A study of the immunological involvement in the development and progression of benign prostate hyperplasia (BPH) looked at the correlation of the clinical parameters of the disease with the immune activation ... Read more